This blog is based on the recent Frost & Sullivan analysis, “Global Molecular Diagnostic Market – Opportunities and Growth Indicators,” authored by Jessica Unice Gadde, Industry Analyst, Healthcare & Life Sciences Practice
The molecular diagnostics industry is consolidating as companies acquire proprietary testing platforms to expand in precision oncology and blood-based diagnostics. These transactions provide the research, commercial, and financial capacity needed to move new tests into routine care. At the same time, digital polymerase chain reaction (dPCR), next-generation sequencing (NGS), CRISPR-associated systems (CRISPR-Cas), and nanotechnology are being combined to improve testing speed, accuracy, and scale.
Unlock Growth in Molecular Diagnostics
Discover how technology convergence, strategic acquisitions, and companion diagnostics are influencing market growth.
NGS is widening access to multi-gene analysis, with companies such as MGI Tech introducing automated sequencing solutions. As laboratories manage increasingly complex genomic data, artificial intelligence (AI) helps interpret results and improve workflow efficiency. Companion diagnostics are also linking validated molecular tests more closely with targeted therapies.
How will your organization respond as molecular diagnostics become more technology-driven and partnership-led?
Listen to our latest podcast on technologies advancing molecular diagnostics and precision medicine.
Top 3 Strategic Imperatives Shaping the Molecular Diagnostics Industry
- Transformative Megatrends: Multi-omics Diagnostics Support Precision Medicine
Increasing disease complexity is driving the adoption of multi-omics diagnostics and integrated biological data analysis. These methods combine different types of biological information to provide a broader view of disease. As more clinical and biological data become available over time, connected platforms are helping turn this information into insights for precision medicine.
- Innovative Business Models: Value-based Molecular Diagnostics
Molecular diagnostics companies are placing greater emphasis on the clinical value of their tests and their effect on patient outcomes. This change is increasing the need for stronger supporting evidence and reimbursement strategies. Companion diagnostic partnerships are reinforcing this model by linking molecular tests with therapy selection and treatment decisions.
- Competitive Intensity: Decentralized Molecular Testing
Demand for faster and more accessible diagnostics is increasing the use of decentralized testing. This model makes molecular tests available across more clinical diagnostics settings instead of limiting them to centralized laboratories. As healthcare systems focus on accessibility and workflow efficiency, distributed testing is becoming an important point of competition.
Growth Restraints Affecting Wider Clinical Adoption
Despite strong growth prospects, several operational and clinical challenges could affect the pace of molecular diagnostics adoption:
- Implementation hurdles: Population-wide DNA testing programs are complex to operate on a large scale. Logistical and operational difficulties may delay implementation and slow market growth.
- Alternative diagnostic technologies: Advanced immunoassays and emerging biosensor-based tests can provide faster results at a lower cost. These alternatives may limit the use of molecular diagnostics in certain applications.
- Shortage of skilled professionals: Integrating patient health information, genomic data, and real-world healthcare results requires advanced data management skills. A shortage of professionals with this expertise may restrict the use of integrated diagnostic systems.
- Limited clinical utility evidence: Some emerging molecular tests do not yet have enough evidence to show how they support clinical care. This remains a key barrier for technologies such as DNA-based population screening.
Key Technology and Investment Megatrends Shaping the Molecular Diagnostics Market
These developments show how the need for faster results, wider access, and detailed genetic analysis is changing molecular testing:
- Rapid Diagnostics Drive Decentralized Molecular Testing
- Demand for faster results and easier access is moving molecular testing beyond centralized laboratories.
- This shift is increasing the use of point-of-care testing (POCT), at-home kits, and direct-to-consumer testing, particularly in infectious disease and chronic care.
- Advances in miniaturization, microfluidics, and AI are supporting the development of portable and rapid testing systems.
- NGS Expands Personalized Medicine Applications
- NGS can analyze multiple genes quickly and cost-effectively, supporting its use in oncology, rare diseases, and reproductive health.
- To widen access to this technology, companies such as MGI Tech are introducing automated NGS systems.
- Engagement with clinicians, researchers, and regulators further support NGS adoption across research and clinical settings.
- Mergers and Acquisitions Reshape Molecular Diagnostics Competition
- Molecular diagnostics companies are using mergers and acquisitions to add products, obtain new technologies, and strengthen R&D capabilities.
- These transactions can shorten commercialization timelines, improve operational efficiency, and increase market penetration.
- Collaborations with start-ups provide another route to emerging technologies and new diagnostic solutions.
Emerging Molecular Diagnostics Companies and Their Core Technologies
These players are applying different technologies to address key needs across cancer, rare disease, and prenatal diagnostics:
| Emerging Player | Core Technology | Key Products and Clinical Applications |
| SOPHiA GENETICS | The cloud-based SOPHiA DDM platform applies AI to genomic, radiomic, and clinical data. | Analyzes multimodal data for cancer and rare disease applications, including liquid biopsy through MSK-ACCESS. |
| Guardant Health | Liquid biopsy examines cancer-related signals found in blood samples. | Guardant360 CDx provides genomic profiling, Guardant Reveal detects minimal residual disease after treatment, and Shield screens for colorectal cancer. |
| BillionToOne | Single-molecule NGS and molecular counting underpin its prenatal and oncology tests. | UNITY Complete screens for single-gene disorders and chromosomal conditions. Northstar Select and Northstar Response identify cancer variants and track tumour burden. |
Growth Opportunities in Molecular Diagnostics
AI-based data analysis and multi-omics liquid biopsy address two pressing needs in molecular diagnostics: interpreting complex test data and monitoring cancer through blood samples.
- AI-integrated Molecular Diagnostics for Clinical Decision Support
Molecular tests are producing growing volumes of genomic, transcriptomic, and biomarker data, increasing the need for integrated analytical platforms. AI-enabled systems can examine these datasets alongside clinical information, helping clinicians interpret genomic findings and make informed treatment decisions. Companies seeking to capitalize this opportunity should:
- Connect AI analytics with sequencing workflows, electronic health records (EHRs), and laboratory systems so that genomic findings can inform clinical decisions.
- Develop automated reporting and variant interpretation tools to shorten analysis time and reduce the workload of bioinformatics specialists.
- Collaborate with software developers, healthcare providers, and pharmaceutical companies to integrate AI-supported molecular tests into clinical practice.
- Multi-omics Liquid Biopsy for Cancer Detection and Monitoring
Multi-omics liquid biopsy combines genomic, epigenomic, transcriptomic, and proteomic signals collected from a blood sample. This non-invasive method can support early cancer detection, tumour profiling, treatment-response assessment, and minimal residual disease monitoring. Moving these tests into clinical use will require companies to:
- Develop platforms that examine genomic mutations, DNA methylation, and circulating tumour DNA (ctDNA) for cancer detection and monitoring.
- Generate clinical evidence for early detection, treatment response, minimal residual disease, and tumour recurrence.
- Work with pharmaceutical companies on biomarker discovery, patient selection, and companion diagnostics for precision oncology.
Future Outlook
Molecular diagnostics is moving closer to clinical workflows and treatment decisions as companion diagnostics, AI-enabled analysis, and decentralized testing gain attention. NGS will continue to support multi-gene analysis, while multi-omics liquid biopsy could extend the role of blood-based testing in early cancer detection and disease monitoring.
Wider clinical use will depend on supporting evidence, faster regulatory pathways, skilled data professionals, and integration with existing laboratory systems. Diagnostic companies will also need to work with healthcare providers, pharmaceutical companies, and technology developers to move new tests from development into routine care.
Frequently Asked Questions About Molecular Diagnostics
What is meant by molecular diagnostics?
Molecular diagnostics refers to laboratory tests that examine DNA, RNA, or related molecular markers to detect, diagnose, or monitor disease. These tests can identify genetic variants, pathogens, and disease-related biomarkers that may inform treatment decisions.
What are the main types of molecular diagnostic tests?
The main types include PCR, NGS, nucleic acid hybridization, microarrays, and isothermal amplification. The method used depends on the disease, sample type, clinical purpose, and genetic or molecular target being examined.
Is molecular diagnostics expensive?
The cost of molecular diagnostics depends on the type of test, number of molecular targets, equipment, and level of data analysis required. Targeted PCR tests are generally less complex than next-generation sequencing (NGS) panels, which may involve sequencing equipment, specialized interpretation, and additional laboratory resources.
What is the most common molecular diagnostic test?
Polymerase chain reaction (PCR) is one of the most common molecular diagnostic tests. It detects genetic material from pathogens or human cells and is widely used for infectious disease testing, genetic analysis, and other applications requiring rapid and accurate molecular detection.
What are some examples of molecular diagnostic tests?
Examples include PCR tests for infectious diseases, genetic tests for inherited conditions, NGS panels for cancer-related variants, prenatal screening, companion diagnostics, and liquid biopsy tests. These tests may also be used to detect minimal residual disease or identify biomarkers that guide treatment selection.
What are the benefits of molecular testing?
Molecular testing can detect small amounts of genetic material with high sensitivity and specificity. Depending on the application, it can support early disease detection, identify pathogens or genetic variants, guide targeted treatment, and monitor disease or treatment response.
Ready to Lead the Transformation?
- Schedule a Growth Strategy Dialog: Align your growth roadmap with Frost & Sullivan’s Visionary Growth Pipeline™ Dialog.
- Engage with Growth Experts: Co-design AI-enabled, data-driven operating models that scale industry-specific and commercial impact.
- Showcase Your Transformational Leadership: Position your organization as a transformation leader through Frost & Sullivan’s Transformational Growth Leadership platform.
- Join the Growth Council: Collaborate with industry leaders shaping the future of your ecosystem.
- Explore Best Practices Recognition: Be recognized for excellence in growth strategy, execution, and customer impact.
- Benchmark Your Industry Positioning on the Frost Radar™: Benchmark your growth performance and innovation strength against industry competitors.
- Tell Your Story: Accelerate awareness, engagement, and revenue growth through integrated brand and demand generation strategies.
